No Data
Centene (NYSE:CNC) Hasn't Managed To Accelerate Its Returns
Barclays Maintains Centene(CNC.US) With Buy Rating, Cuts Target Price to $90
How Is Centene's Stock Performance Compared to Other Healthcare Stocks?
Barclays Adjusts Price Target on Centene to $90 From $104, Maintains Overweight Rating
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Here's Why We Think Centene (NYSE:CNC) Might Deserve Your Attention Today